NCT03129477: TELECOPD

TELE-monitoring in Chronic Obstructive Pulmonary Disease

Status unknown NA Last updated 23 July 2018

What this trial tests

NA trial testing Telemonitoring in noninvasive ventilation in COPD in 50 participants. Status unknown.

Timeline

1 January 2019

Primary endpoint
31 December 2019

31 December 2019

Quick facts

Lead sponsor	Conde, Bebiana, M.D.
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	50
Start date	1 January 2019
Primary completion	31 December 2019
Estimated completion	31 December 2019
Sites	1 location across Portugal

Drugs / interventions tested

• Telemonitoring in noninvasive ventilation

Conditions studied

• COPD — all drugs for COPD →

Sponsor

Conde, Bebiana, M.D.

Who can join

18 and older, any sex, with COPD. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

COPD is the fourth cause of death worldwide and it is expected to be the third in 2020.

Non-invasive ventilation (NIV) has a positive impact in reducing mortality related to chronic respiratory failure in stable patients with COPD. Moreover, the addition of home NIV to home oxygen therapy reduces hospital admissions and improves patients outcomes.

Patients monitoring is crucial. It is increasingly recognized the potential of telemedicine in reducing morbidity and mortality, as well as healthcare utilisation and its associated costs. In particular, home telemonitoring (TM)- a technology measuring patients'clinical parameters and symptoms at home and allowing communication between healthcare professionals and patients over distance- has gained much attention. However, despite a growing body of evidence for TM in the management of COPD and other chronic diseases, the benefit of telemonitoring for Home mechanical ventilation concerning clinical and economic outcomes remains to be clearly demonstrated.

The study aims to assess the impact that telemonitoring would have NIV efficacy, patient quality of life and satisfaction, through a prospective randomized study.The primary endpoint is the time for appropriate adaptation and therapy efficacy, defined as average SatO2 to 90% in 24h oximetry.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Telehealth interventions: remote monitoring and consultations for people with chronic obstructive pulmonary disease (COPD).
   Janjua S, Carter D, Threapleton CJ, Prigmore S, et al · · 2021 · cited 70× · PMID 34693988 · DOI 10.1002/14651858.cd013196.pub2